English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The authors had developed a new experimental adjuvant based on squalene and  its efficacy was tested on target domestic animals - cats and dogs by means  of different rabies vaccines. In this experiment the authors compared the  immune response on the rabies vaccine without adjuvant and with aluminium  adjuvant or experimental squalene adjuvant, respectively. The level of rabies  antibodies was determined by rapid fluorescence focus inhibition test on days  14, 30, 90 and 450 (dogs), and on days 14, and 30 (cats), respectively. The  rabies antibodies level on day 14 still did not reache the protection level  determined by WHO. On day 30 each of the vaccines induced an adequate  response, while the most effective seemed to be the vaccine with experimental  squalene adjuvant. On day 450 the antibodies level decreased, but the average  level was over the protection value, when the experimental  squalene-adjuvanted vaccine was used. The level of rabies antibodies did not  achieve the protection value in 2 from 10 dogs in this group. There is an  open question, if it is sufficient to use only one dose of rabies vaccine for  safe primovaccination of young animals

A new rabies vaccine with an experimental adjuvant for domestic animals